Incannex Healthcare Inc. has announced positive results from its Phase 2 clinical trial of PSX-001, a psilocybin-assisted psychotherapy treatment for Generalised Anxiety Disorder (GAD). The trial demonstrated statistically significant and clinically meaningful improvements in anxiety, mood, disability, and quality of life measures. These findings position PSX-001 as a leading psilocybin-assisted therapy currently in development. The company plans to initiate a multi-jurisdiction Phase 2 clinical trial and is seeking strategic partnerships to enhance development and global access. The results were presented as part of the company's ongoing efforts to advance its clinical pipeline.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-080509), on August 26, 2025, and is solely responsible for the information contained therein.